25,564 results match your criteria Drug Eruptions


Delayed granulomatous eruption of the nose associated with ruxolitinib.

JAAD Case Rep 2020 Jul 13;6(7):646-649. Epub 2020 May 13.

Division of Dermatology and Cutaneous Surgery, Department of Medicine, UT Health San Antonio, San Antonio, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317688PMC

Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors.

Dermatol Online J 2020 Mar 15;26(3). Epub 2020 Mar 15.

School of Medicine, University of California Riverside, Riverside, CA.

Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inherited or may occur sporadically with multiple red-brown, thin plaques in a photodistribution. The condition more often affects middle-aged women and is often recalcitrant to therapy. In rare literature reports, systemic medications can trigger exacerbation or promote inflammation in pre-existing lesions of DSAP. Read More

View Article

Download full-text PDF

Source

Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center.

Sci Rep 2020 Jun 17;10(1):9774. Epub 2020 Jun 17.

Division of Clinical Dermatology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.

Erythroderma is characterized by erythema and scaling affecting more than 80% of the body surface area. It is potentially life-threatening, and diagnosis of the underlying disease is a challenge. Despite laboratory improvements, many cases remain idiopathic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-66040-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300014PMC

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.

Adv Rheumatol 2020 06 9;60(1):32. Epub 2020 Jun 9.

Pontifícia Universidade Católica de Campinas, Campinas, Brazil.

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-020-00134-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202PMC

Drug eruptions associated with tumor therapy: Great imitators.

Clin Dermatol 2020 Mar - Apr;38(2):208-215. Epub 2019 Oct 24.

Department of Dermatology, University of Illinois College of Medicine at Chicago, Chicago, Illinois, USA. Electronic address:

Many studies have investigated cutaneous reactions to antitumor drugs and found them to be quite numerous. We describe drug eruptions that may be associated with different therapies by class: antimetabolite chemotherapeutics, genotoxic agents, spindle inhibitors, signal transduction inhibitors, and immunotherapies. Methotrexate is most often associated with mucocutaneous reactions, alkylating antimetabolite agents with hyperpigmentation, and platinum antimetabolite agents with type I IgE-mediated hypersensitivity reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.006DOI Listing
October 2019

Drug eruptions: Great imitators.

Authors:
Chia-Yu Chu

Clin Dermatol 2020 Mar - Apr;38(2):193-207. Epub 2019 Oct 24.

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Drug eruptions are among the great masqueraders that sometimes cause diagnostic challenges in clinical practice. Pharmacologic agents may induce skin changes, sharing the same pathophysiologic mechanisms of specific dermatoses, or inducing drug eruptions with different pathologic mechanisms that have similar clinical presentations. The former conditions are usually called drug-induced skin diseases, whereas the latter conditions are termed "dermatosis-like drug eruptions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.005DOI Listing
October 2019

Contact dermatitis: A great imitator.

Clin Dermatol 2020 Mar - Apr;38(2):176-192. Epub 2019 Oct 24.

Department of Dermatology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.

Contact dermatitis (CD) refers to a group of cutaneous diseases caused by contact with allergens or irritants. It is characterized by different stages of an eczematous eruption and has the ability to mimic a wide variety of dermatologic conditions, including inflammatory dermatitis, infectious conditions, cutaneous lymphoma, drug eruptions, and nutritional deficiencies. Irritant CD and allergic CD are the two main presentations of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.003DOI Listing
October 2019

Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.

Medicine (Baltimore) 2020 Jun;99(23):e20510

School of Nursing, College of Medicine, Chang Gung University.

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is the primary treatment option for patients with non-small cell lung cancer (NSCLC). However, one of the major adverse effects associated with this therapy is skin toxicity, which impacts the patient's quality of life. This study aimed to describe the severities and locations of skin toxicity, and to analyze their association with the quality of life in patients with advanced NSCLC who received EGFR-TKI therapy as first-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020510DOI Listing

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms.

Inflamm Res 2020 Aug 2;69(8):745-756. Epub 2020 Jun 2.

Department of Dermatology, Faculdade de Medicina do ABC, Príncipe de Gales, Avenida Príncipe de Gales, 821, Santo André, SP, 09060-650, Brazil.

Background: SARS-Cov-2 is a single-stranded RNA virus, a Betacoronavirus, composed of 16 non-structural proteins, with specific roles in replication of coronaviruses. The pathogenesis of COVID-19 is not yet fully understood. The virus and host factors interplay among distinct outcomes of infected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00011-020-01370-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266387PMC
August 2020
2.143 Impact Factor

Clindamycin-induced acute generalized exanthematous pustulosis: A case report.

Medicine (Baltimore) 2020 May;99(21):e20389

Hematology Unit, Medical Specialty Center, Bangkok Hospital Hat Yai, Bangkok Dusit Medical Services, Hat Yai, Songkhla, Thailand.

Rationale: Acute generalized exanthematous pustulosis (AGEP) is a severe pustular cutaneous adverse drug reaction. Sterile, non-follicular pustules overlying the erythematous skin characterize this reaction.

Patient Concerns: A 30-year-old Asian women presented with sterile, non-follicular lesions with pus-fluid levels on her back 2 days after taking clindamycin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249952PMC
May 2020
5.723 Impact Factor

Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.

J Clin Pharm Ther 2020 Jun 1. Epub 2020 Jun 1.

Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

What Is Known And Objective: Imatinib mesylate (IM) is the first-line therapy for unresectable or metastatic gastrointestinal stromal tumours (GISTs). Here, we report a case of successful progressive dose optimization by therapeutic drug monitoring (TDM) for a patient with GISTs who developed IM-associated serious cutaneous reactions.

Case Description: A 72-year-old female patient received IM at a dose of 400 mg/day for GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.13201DOI Listing

Spectrum of Cutaneous Adverse Drug Reactions to Anti-tubercular Drugs and Safe Therapy after Re-challenge - A Retrospective Study.

Indian Dermatol Online J 2020 Mar-Apr;11(2):177-181. Epub 2020 Mar 9.

Department of Dermatology, Venereology and Leprosy, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.

Background: Tuberculosis (TB) is a major global health problem and leading cause of death. Anti-tubercular therapy (ATT) can lead to various adverse effects including cutaneous reactions. Re-challenge remains the only option to restart the safe therapy with limited number of most efficient primary ATT drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_133_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247648PMC

[Immunotherapy with immune checkpoint inhibitor and skin toxicity].

Rev Med Suisse 2020 May;16(695):1086-1091

Service d'oncologie, Centre hospitalier du Valais romand, Hôpital du Valais, Avenue du Grand-Champsec 86, 1950 Sion.

Dermatologic toxicities appear to be the most prevalent immunotherapy related adverse effects, both with anti-PD-1 and anti-CTLA-4 agents, as well as with the newly developed anti-PD-L1. They occur in more than one-third of the patients treated with immune check point inhibitors, regardless of the cancer being treated. They mainly manifest in the form of self-limiting maculopapular rashes and pruritus. Read More

View Article

Download full-text PDF

Source

TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.

Ther Adv Respir Dis 2020 Jan-Dec;14:1753466620926800

Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd, Hangzhou, Zhejiang 310009, China.

Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFα, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753466620926800DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243041PMC

[European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology].

Hautarzt 2020 Jul;71(7):542-552

Hautklinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Deutschland.

Background And Objectives: Treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe cases, the use of immunoglobulin is not generally based on data from randomized controlled trials usually required for evidence-based medicine. Since the indications for the use of IVIg are rare, it is unlikely that such studies will be available in the foreseeable future. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-020-04610-6DOI Listing

Correlation between serum TARC levels and eczematous drug eruption following oral challenge test with clonazepam.

Clin Exp Dermatol 2020 May 18. Epub 2020 May 18.

Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan.

A 65-year-old Japanese man presented with linear erythema and red papules that first occurred on his shoulders and front chest, and gradually spread over his entire body. Prior to the development of the eruptions, he had a sleep disorder and had been treated with clonazepam for 5 months. He had also regularly been taking azilsartan for hypertension for 1 year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14293DOI Listing

Cutaneous signs in COVID-19 patients: A review.

Dermatol Ther 2020 May 10:e13549. Epub 2020 May 10.

Department of Dermatology and Venereology, University of Rome G. Marconi, Rome, Italy.

Coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the epithelium of the airways. With the increasing involvement of dermatologist in management of this crisis, cutaneous symptoms gained more and more attention. In this review, we will describe cutaneous symptoms of patients of all ages in association with COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273098PMC

The complexity of T cell-mediated penicillin hypersensitivity reactions.

Allergy 2020 May 8. Epub 2020 May 8.

Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, 3800, Victoria, Australia.

Penicillin refers to a group of beta-lactam antibiotics that are the first-line treatment for a range of infections. However, they also possess the ability to form novel antigens, or neoantigens, through haptenation of proteins and can stimulate a range of immune-mediated adverse reactions - collectively known as drug hypersensitivity reactions (DHRs). IgE-mediated reactions towards these neoantigens are well studied, however, IgE-independent reactions are less well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/all.14355DOI Listing

Drug Reaction, Eosinophilia, and Systemic Symptoms (DRESS) Syndrome As a Mimicker of Spinal Infection: Awareness for Spinal Surgeons.

Cureus 2020 Apr 1;12(4):e7503. Epub 2020 Apr 1.

Spine Surgery, Salford Royal Hospital NHS Foundation Trust, Salford, GBR.

Drug reaction, eosinophilia, and systemic symptoms (DRESS) syndrome is a delayed severe drug hypersensitivity (type IVb) syndrome with cutaneous eruption, hematological abnormalities, and multi-organ involvement. The wide spectrum of the disease manifestations, long-term sequelae, and high mortality rates are a clinical concern. Though not commonly reported in spinal surgery patients, the use of long-term antibiotics is a potential causative agent in spinal infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195205PMC

Cutaneous manifestations in COVID-19: Lessons learned from current evidence.

J Am Acad Dermatol 2020 Jul 24;83(1):e57-e60. Epub 2020 Apr 24.

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194618PMC

Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.

Expert Rev Anticancer Ther 2020 Apr 28:1-6. Epub 2020 Apr 28.

Professor of Dermatology and Director of Cutaneous Lymphoma Program, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T-cell lymphoma characterized by a poor prognosis. Treatments are associated with high rates of relapse, and thus there exists an unmet medical need for new, improved therapies. Mogamulizumab is a novel defucosylated monoclonal antibody targeting C-C chemokine receptor 4 that eradicates malignant cells via antibody-dependent cellular cytotoxicity (ADCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1760096DOI Listing

Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives.

Virusdisease 2020 Apr 20:1-9. Epub 2020 Apr 20.

3Neuroscience Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab 142001 India.

The present outbreak associated with corona virus [CoVs] in China which is believed to be one of the massive eruptions towards mankind in 2019-2020. In the present scenario CoVs has been transmitted to the European and American regions through the travellers from wide spread countries like China and Japan. The viral disease is spreading through the contact in any form by the infected persons or patients and creating huge risk of mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13337-020-00580-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167492PMC

Atorvastatin-induced Lichenoid Drug Eruption: A Case Report and Review of Statin-associated Cutaneous Adverse Events.

Cureus 2020 Mar 1;12(3):e7155. Epub 2020 Mar 1.

Dermatology, San Diego Family Dermatology, National City, USA.

Statin medications [3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors] are generally used to treat hypercholesterolemia. Lichenoid drug eruptions are a potential cutaneous side effect of medications including antibiotics, antimalarials, and statins. This drug eruption can mimic features of idiopathic lichen planus in clinical presentation and pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108677PMC

Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.

Dermatol Ther 2020 05 16;33(3):e13380. Epub 2020 Apr 16.

Rutgers New Jersey Medical School, Newark, New Jersey, USA.

A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. It is distinguishable by its longer incubation period, more varied morphology with initially urticarial and later targetoid and arcuate plaques, recalcitrance to therapy and longer duration. Given the anticipated surge in the use of hydroxychloroquine due to its reported benefits in those with coronavirus disease 2019, specific recognition of this entity is pivotal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235477PMC

Antiepileptic Hypersensitivity Syndrome to Phenobarbital: A Case Report.

Iran J Allergy Asthma Immunol 2019 Oct 23;18(5):567-571. Epub 2019 Oct 23.

Department of Pediatrics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Phenobarbital is still one of the most commonly used medical treatments for different types of seizures. It has numerous different side-effects. Antiepileptic hypersensitivity syndrome (AHS) is a rare and potentially life-threatening adverse reaction to aromatic anticonvulsants such as phenobarbital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18502/ijaai.v18i5.1926DOI Listing
October 2019

DRESS syndrome due to iodinated contrast medium.

N Z Med J 2020 04 3;133(1512):93-95. Epub 2020 Apr 3.

Haematology, Canterbury District Health Board, Christchurch.

View Article

Download full-text PDF

Source

Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata.

Dermatol Online J 2020 Feb 15;26(2). Epub 2020 Feb 15.

Department of Dermatology, School of Medicine, University of Patras.

Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies. There are only four reported cases of EN during oral isotretinoin therapy to our knowledge, all of them occurring in patients with severe acne. Since acne itself can trigger EN, the question as to whether there is indeed a causative relationship between isotretinoin and EN in the reported cases remains to be elucidated. Read More

View Article

Download full-text PDF

Source
February 2020

Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap.

Dermatol Online J 2020 Feb 15;26(2). Epub 2020 Feb 15.

Cedars Dermatology, Cedars Sinai Medical Group, CA.

Thiotepa is a common alkylating agent known to precipitate cutaneous reactions consistent with toxic erythema of chemotherapy, including erythema and hyperpigmentation. Herein, we describe an atypical case of malignant intertrigo involving preferential erythema and desquamation not only of skin folds but also of occluded areas after thiotepa-based conditioning. The diagnosis was complicated by concurrent stomatitis and oral petechiae in the setting of autologous stem cell transplant 11 days prior for diffuse large B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
February 2020

The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of electronic medical records.

Dermatol Online J 2020 Feb 15;26(2). Epub 2020 Feb 15.

Dermatologist, San Diego Family Dermatology, National City, CA Department of Dermatology, Touro University California College of Osteopathic Medicine, Vallejo, CA.

A morbilliform drug eruption is the most common condition leading to a dermatology consultation for a patient in the hospital. Timing is an important diagnostic tool since the onset of a skin rash usually takes place within days-to-weeks of the start of the implicated drug. A comprehensive, thorough, and reliable drug history by the clinician is essential. Read More

View Article

Download full-text PDF

Source
February 2020

The life-threatening eruptions of immune checkpoint inhibitor therapy.

Clin Dermatol 2020 Jan - Feb;38(1):94-104. Epub 2019 Oct 25.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA. Electronic address:

Immune checkpoint inhibitors (ICPi) have emerged as a new frontier of cancer therapy. Although monoclonal antibodies to cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1) have revolutionized oncologic management, these agents may result in a spectrum of immune-related adverse events (irAE) of which dermatologic toxicities are among the most frequent. Prompt recognition and management of irAE is essential for dermatologists caring for the expanding population of cancer patients exposed to these drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.015DOI Listing
October 2019

The life-threatening eruption in HIV and immunosuppression.

Clin Dermatol 2020 Jan - Feb;38(1):52-62. Epub 2019 Nov 16.

The Sector of Dermatology and Post-Graduation Course in Dermatology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Brazil.

Immunosuppressed patients frequently have skin diseases of mild to moderate intensity. Diagnosis as well as treatment should be performed early to avoid important complications for these patients. Skin eruptions are among these problems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.014DOI Listing
November 2019

The rash with mucosal ulceration.

Clin Dermatol 2020 Jan - Feb;38(1):35-41. Epub 2019 Oct 25.

Sector of Dermatology and Post-Graduation Course in Dermatology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Brazil. Electronic address:

A rash is a disseminated eruption of cutaneous lesions with great variation in appearance, cause, and severity. When the physician is facing a rash, the history and physical examination of the patient are extremely important for the identification of the disease and its causal agent. There are various causes for a rash, which may be infectious, allergic, or rheumatologic, besides many others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.019DOI Listing
October 2019

Fatal pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: Three case reports.

Medicine (Baltimore) 2020 Mar;99(12):e19431

Department of Respiratory.

Rationale: Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are extremely rare but potentially life-threatening disorders. We presented 3 fatal pediatric SJS/TEN cases.

Patient Concerns: Our patients had some severe complications such as septic shock, respiratory failure and obliterans bronchiolitis (BO) etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019431DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220343PMC
March 2020
5.723 Impact Factor

Cytokines/Chemokines: Novel Biomarkers Associated with Severe Cutaneous Adverse Reactions.

J Interferon Cytokine Res 2020 Apr 20;40(4):172-181. Epub 2020 Mar 20.

Department of Dermatology, The Second Affiliated Hospital, WanNan Medical College, Wuhu, China.

Although the incidence of severe cutaneous adverse reactions (SCARs) is very low, if it is not diagnosed and treated in time, it can not only cause skin and mucous membrane involvement, but can also cause multiple organ failure and even death. The diagnostic criteria and treatment guidelines for severe drug eruptions have not been unified. Many medical centers have used human leukocyte antigen alleles to diagnose SCARs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jir.2019.0012DOI Listing

Genital Ulcers: Differential Diagnosis and Management.

Authors:
Michelle A Roett

Am Fam Physician 2020 Mar;101(6):355-361

Georgetown University Medical Center, MedStar Georgetown University Hospital, Washington, DC, USA.

Genital ulcers may be located on the vagina, penis, and anorectal or perineal areas and may be infectious or noninfectious. Herpes simplex virus is the most common cause of genital ulcers in the United States. A diagnosis of genital herpes simplex virus infection is made through physical examination and observation of genital lesions. Read More

View Article

Download full-text PDF

Source

Biologics in Leprosy: A Systematic Review and Case Report.

Am J Trop Med Hyg 2020 05;102(5):1131-1136

London School of Hygiene and Tropical Medicine, London, United Kingdom.

Tumor necrosis factor (TNF)-α inhibitors increase susceptibility to tuberculosis, but the effect of biologics on susceptibility to leprosy has not been described. Moreover, biologics may play a role in treating erythema nodosum leprosum (ENL). The objectives of this systematic review were to determine whether the development of clinical leprosy is increased in patients being treated with biologics and to assess the use of biologics in treating leprosy reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4269/ajtmh.19-0616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204592PMC

Cutaneous Drug Eruptions in Pediatrics-A Primer.

Pediatr Ann 2020 Mar;49(3):e132-e139

Cutaneous adverse drug reactions (ADRs) are commonly seen in the pediatric population in both inpatient and outpatient settings and are important to identify, evaluate, and appropriately manage. Early recognition and proper classification of a cutaneous drug reaction allows the clinician the ability to narrow in on a culprit drug and determine whether the medication is safe to continue. This review discusses the clinical presentation, categorization, and management of cutaneous ADRs in the pediatric population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3928/19382359-20200224-01DOI Listing

Toxic epidermal necrolysis after radiotherapy for pleomorphic liposarcoma.

Dermatol Online J 2020 Jan 15;26(1). Epub 2020 Jan 15.

Department of Dermatology, University of Rochester Medical Center, Rochester, NY.

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are life-threatening, cutaneous reactions often associated with culprit drugs. A growing body of knowledge has deepened our understanding of the pathophysiology and clarified mechanisms such as drug-specific cytotoxicity mediated by T-cells, genetic linkage with HLA and non-HLA genes, TCR restriction, and cytotoxicity mechanisms. Physicians should broadly consider the etiology of SJS/TEN in order to better understand treatment strategies as well as identify which patients may be at risk for developing this condition. Read More

View Article

Download full-text PDF

Source
January 2020

Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.

Dermatol Online J 2020 Jan 15;26(1). Epub 2020 Jan 15.

Division of Dermatology, The Ohio State University Department of Internal Medicine, Columbus, OH.

The combination of dabrafenib and trametinib is an important immunotherapy option for patients with BRAF V600 mutation-positive melanoma. This regimen has been reported to cause cutaneous eruptions. However, hair dysmorphology is not a reported side effect to these or any other medications to date. Read More

View Article

Download full-text PDF

Source
January 2020

Successful Therapy of Crohn's Disease-Associated Pulmonary Necrobiotic Nodules on Ustekinumab Therapy.

Am J Gastroenterol 2020 04;115(4):632-634

Department of Medicine 1, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000571DOI Listing

Twelve cases of acneiform eruptions while on anti-CTLA4 therapy.

Support Care Cancer 2020 Jun 9;28(6):2499-2502. Epub 2020 Mar 9.

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FCT 11.5000, Unit 1452, Houston, TX, 77030-4009, USA.

We present the first detailed report of acneiform eruptions in patients on CTLA-4 inhibitor therapy. Acneiform eruptions commonly occur (up to 75-100%) as a cutaneous adverse event associated with EGFR inhibition; however, acneiform eruptions have not been highly reported as a cutaneous adverse event associated with CTLA-4 inhibitor therapy. We conducted a retrospective chart review of our institution's database to assess cutaneous adverse events associated with ipilimumab and tremelimumab, identifying 12 patients with acneiform eruptions (2 on tremelimumab and 10 on ipilimumab). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05381-5DOI Listing

[Cardiologists' perceptions on Behcet's disease and its cardiovascular lesions: a single center analysis].

Zhonghua Nei Ke Za Zhi 2020 Mar;59(3):222-224

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

To analyze the perceptions of cardiovascular specialists about Behcet's disease and its cardiovascular lesions in Beijing Anzhen Hospital, Capital Medical University. A survey using questionnaires was conducted among cardiovascular specialists in the hospital, the differences among groups were analyzed with χ(2) analyses. Less than half of the cardiovascular specialists were familiar with the diagnostic criteria of Behcet's disease (32. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2020.03.010DOI Listing

Multiple Fixed Drug Eruption Mimicking Parapsoriasis en Plaque in a Patient with Hepatitis C Virus Infection.

Case Rep Dermatol 2020 Jan-Apr;12(1):25-32. Epub 2020 Feb 4.

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.

Although hepatitis C virus (HCV) infection is often associated with extrahepatic cutaneous manifestations such as lichen planus, it is unclear whether HCV or HCV-specific immune responses play a pathophysiological role in the development of HCV-related cutaneous diseases. We recently treated a patient who developed parapsoriasis en plaque-like lesions after ingestion of various drugs. She showed hypersensitivity to multiple drugs after interferon therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036541PMC
February 2020

Comparison of racial distribution of photodermatoses in USA academic dermatology clinics: A multicenter retrospective analysis of 1080 patients over a 10-year period.

Photodermatol Photoimmunol Photomed 2020 May 12;36(3):233-240. Epub 2020 Mar 12.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Background: Previous studies at single academic institutions have identified variations in the prevalence of photodermatoses among racial groups. The purpose of the study was to compare the distribution of photodermatoses between Whites and Blacks at four academic medical centers in the USA.

Methods: A retrospective chart review was performed at four institutions' general dermatology clinics using diagnoses consistent with the International Classification of Disease (ICD), Ninth and Tenth Revisions, codes related to photodermatoses between August 2006 and August 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12543DOI Listing

Severe cutaneous adverse reactions (SCARs) to drugs in Latin America: RACGRAD study.

J Investig Allergol Clin Immunol 2020 02 25. Epub 2020 Feb 25.

Fundación Valle del Lili, Universidad Icesi, Cali, Colombia.

Background And Objective: Severe cutaneous adverse reactions to drugs (SCARs), have a high morbidity, mortality and present sequelae. Objective: To characterize patients with SCARs in eight health care institutions in Latin America.

Methods: Cross-sectional, descriptive, multicenter, Latin American study of patients diagnosed with SCARs, between January 2009 and December 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18176/jiaci.0497DOI Listing
February 2020

Lichen planopilaris induced by infliximab: A case report.

SAGE Open Med Case Rep 2020 28;8:2050313X20901967. Epub 2020 Jan 28.

Division of Dermatology, Department of Medicine, Queen's University and Hotel Dieu Hospital, Kingston, ON, Canada.

Infliximab is a tumor necrosis factor-alpha inhibitor used to treat a range of inflammatory diseases. Most reports of cutaneous eruptions from tumor necrosis factor-alpha inhibitors have described the paradoxical development of psoriasis or psoriasiform drug reaction. In our report, we present a 31-year-old female with inflammatory bowel disease who developed an unusual lichenoid drug reaction to infliximab involving the hair follicles, resulting in progressive global alopecia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X20901967DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987482PMC
January 2020

Characteristics of patients hospitalized for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) at a Level 1 trauma center.

Dermatol Online J 2019 Dec 15;25(12). Epub 2019 Dec 15.

Department of Dermatology, University of California, Davis, CA.

The purpose of this study is to further characterize the population that is hospitalized for a severe cutaneous drug reaction or that developed once during their hospitalization. We conducted a chart review of patients seen by a dermatologist at the University of California Davis Medical Center for the diagnosis of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Between January 2000 and July 2018, 25 cases of DRESS were diagnosed using RegiSCAR criteria. Read More

View Article

Download full-text PDF

Source
December 2019

Bullous Drug Reactions.

Authors:
Maja Mockenhaupt

Acta Derm Venereol 2020 02 12;100(5):adv00057. Epub 2020 Feb 12.

Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center - University of Freiburg, Hauptstrasse 7, DE-79104 Freiburg, Germany.

Bullous drug eruptions are infrequent, but because they pose a challenge both to affected patients and to treating physicians they are considered to be the most severe cutaneous adverse reactions (SCAR). It is important to recognize these conditions and to differentiate them from other clinical entities involving blister formation. There may be early signs and symptoms that indicate a severe bullous drug eruption even before blisters and erosions of the skin and mucous membranes become obvious. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3408DOI Listing
February 2020

Clinical profile of cutaneous adverse drug reactions: a retrospective study of 1883 hospitalized patients from 2007 to 2016 in Shanghai, China.

Eur J Dermatol 2020 Feb;30(1):24-31

Department of Dermatology, Huashan Hospital Affiliated to Fudan University.

Background: Cutaneous adverse drug reactions (CADRs) are drug-induced skin reactions with or without systemic involvement, ranging from mild maculopapular exanthema (MPE) to life-threatening severe CADRs (S-CADRs). Due to their unpredictability and severity, early recognition of suspected causative drugs is highly recommended. However, the profile of CADRs remains unknown in China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2020.3713DOI Listing
February 2020

Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.

J Pathol 2020 04 6;250(4):452-463. Epub 2020 Mar 6.

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used as a treatment for non-small-cell lung cancer. There have been some reports of EGFR-TKIs being associated with vascular adverse events. We found that EGFR-TKIs decreased the proliferation of HMEC-1s (immortalized human dermal microvascular endothelial cells) and HMVECs (human dermal microvascular endothelial cells), and also inhibited the phosphorylation of EGFR and ERK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5393DOI Listing